Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 29, 2018
Event: Final closing of a previously announced private placement of Common Stock and warrants.
Key Financial Metrics
- Shares Sold: 300,798 shares of Common Stock.
- Purchase Price: $2.27 per share.
- Gross Proceeds: Approximately $680,000 (prior to deducting placement agent fees and expenses).
- Warrants Issued: One warrant per share purchased; exercise price of $2.724 per share.
- Placement Agent Compensation: Approximately $41,000 cash plus a warrant to purchase up to 18,048 shares at $2.724 per share.
- Debt and Liquidity: The filing text does not provide specific values for total debt, cash on hand, or liquidity ratios outside of the proceeds from this transaction.
Material Changes
This filing represents the final closing of the Company's private placement. The transaction resulted in an immediate increase in equity capital of approximately $680,000. The issuance includes full ratchet anti-dilution protection for the Common Stock (but not the Warrants) until the Company raises an additional $20.0 million in cash or assets.
Guidance, Outlook, and Risks
- Use of Proceeds: Funds are designated to fund research and development of the lead product candidate, PCS-499, including clinical trial activities, and for general corporate purposes.
- Anti-Dilution Risk: The full ratchet provision requires the purchase price to be adjusted downward if the Company issues equity at a price below $2.27 per share (or $0.01 if issued without consideration) before raising an additional $20.0 million. This could significantly increase the number of shares outstanding for future investors.
- Exemptions: Securities were sold pursuant to Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the total aggregate proceeds raised in the entire private placement series, as this filing only covers the final closing of $680,000.
- Confirm the current cash balance and burn rate to assess runway for the PCS-499 clinical trials.
- Review the full terms of the ratchet anti-dilution provision to understand potential dilution scenarios if future financing occurs below $2.27 per share.
- Check for any subsequent equity issuances that may have triggered the anti-dilution adjustment since June 29, 2018.